



23 June 2021

Incanthera plc
("Incanthera" or the "Company")

Result of AGM 2021

Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in oncology and dermatology, held its AGM earlier today, in accordance with COVID-19 guidance. The Company is pleased to announce that all resolutions were duly passed.

The Company would like to thank all Shareholders who returned their Proxy form and for their compliance with the current Government measures surrounding non-essential travel and public gatherings.

For further enquiries:

Incanthera plc
www.incanthera.com

Tim McCarthy, Chairman +44 (0) 7831 675747
tim.mccarthy@incanthera.com

Simon Ward, Chief Executive Officer +44 (0) 7747 625506
simon.ward@incanthera.com

Suzanne Brocks, Head of Communications +44 (0) 7776 234600
suzanne.brocks@incanthera.com

Aquis Exchange Corporate Adviser: +44 (0) 20 7213 0880
Cairn Financial Advisers LLP
Jo Turner/James Lewis

Broker: +44 (0) 20 3815 8880
Stanford Capital Partners Ltd
Patrick Claridge/John Howes/Bob Pountney

Notes to Editors

Incanthera is a specialist oncology company focused on innovative technologies in oncology and dermatology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.

The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and the Company is now focussed upon delivering Sol to a commercial partner.

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.

Incanthera's strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

For more information on the Company please visit: www.incanthera.com

[@incantherapl](#)